Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 6/2021

01.10.2021 | Case Report

Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a chemotherapy regimen containing cisplatin and irinotecan

verfasst von: Hiromitsu Maehira, Hiroya Iida, Haruki Mori, Nobuhito Nitta, Aya Tokuda, Katsushi Takebayashi, Sachiko Kaida, Toru Miyake, Akiko Matsubara, Masaji Tani

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic acinar cell carcinoma is a rare tumor of the pancreas, and patients with such tumors rarely have a pathological complete response to treatment. Herein, we present a case involving a 48-year-old woman with a pancreatic tail mass. The pancreatic mass was connected to splenic and portal vein thrombosis. Distal pancreatectomy and removal of portal vein tumor thrombosis were performed. Ten months after surgery, multiple liver metastases and local recurrence in the pancreatic bed were detected, and chemotherapy was administered through the administration of a regimen containing both cisplatin and irinotecan. After seven courses of the cisplatin-plus-irinotecan regimen had been administered, computed tomography revealed that the patient had a partial response to treatment. Radical resection of multiple liver metastases and the locally recurrent tumor was performed. Pathological examination did not reveal the presence of carcinoma in any of the resected specimens. Thus, this case involves a pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a regimen containing both cisplatin and irinotecan. Our findings reveal that the administration of the cisplatin-plus-irinotecan regimen may be an option for the management of such tumors.
Literatur
1.
Zurück zum Zitat Williams JA. Regulation of acinar cell function in the pancreas. Curr Opin Gastroenterol. 2010;26:478–83.CrossRef Williams JA. Regulation of acinar cell function in the pancreas. Curr Opin Gastroenterol. 2010;26:478–83.CrossRef
2.
Zurück zum Zitat Holen KD, Klimstra DS, Hummer A, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol. 2002;20:4673–8.CrossRef Holen KD, Klimstra DS, Hummer A, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol. 2002;20:4673–8.CrossRef
3.
Zurück zum Zitat Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 2004;28:219–30.CrossRef Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 2004;28:219–30.CrossRef
4.
Zurück zum Zitat Kitagami H, Kondo S, Hirano S, et al. Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas. 2007;35:42–6.CrossRef Kitagami H, Kondo S, Hirano S, et al. Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas. 2007;35:42–6.CrossRef
5.
Zurück zum Zitat Schmidt CM, Matos JM, Bentrem DJ, et al. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12:2078–86.CrossRef Schmidt CM, Matos JM, Bentrem DJ, et al. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008;12:2078–86.CrossRef
6.
Zurück zum Zitat Glazer ES, Neill KG, Frakes JM, et al. Systematic review and case series report of acinar cell carcinoma of the pancreas. Cancer Control. 2016;23:446–54.CrossRef Glazer ES, Neill KG, Frakes JM, et al. Systematic review and case series report of acinar cell carcinoma of the pancreas. Cancer Control. 2016;23:446–54.CrossRef
7.
Zurück zum Zitat Wisnoski NC, Townsend CM Jr, Nealon WH, et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141–8.CrossRef Wisnoski NC, Townsend CM Jr, Nealon WH, et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141–8.CrossRef
8.
Zurück zum Zitat Wang Y, Wang S, Zhou X, et al. Acinar cell carcinoma: a report of 19 cases with a brief review of the literature. World J Surg Oncol. 2016;14:172.CrossRef Wang Y, Wang S, Zhou X, et al. Acinar cell carcinoma: a report of 19 cases with a brief review of the literature. World J Surg Oncol. 2016;14:172.CrossRef
9.
Zurück zum Zitat Seth AK, Argani P, Campbell KA, et al. Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg. 2008;12:1061–7.CrossRef Seth AK, Argani P, Campbell KA, et al. Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg. 2008;12:1061–7.CrossRef
10.
Zurück zum Zitat Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16:815–37.CrossRef Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16:815–37.CrossRef
11.
Zurück zum Zitat Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 2021;50:77–82.CrossRef Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 2021;50:77–82.CrossRef
12.
Zurück zum Zitat Busch E, Werft W, Bougatf N, et al. Metastatic acinar cell carcinoma of the pancreas: a retrospective cohort study on systemic chemotherapy and review of the literature. Pancreas. 2021;50:300–5.CrossRef Busch E, Werft W, Bougatf N, et al. Metastatic acinar cell carcinoma of the pancreas: a retrospective cohort study on systemic chemotherapy and review of the literature. Pancreas. 2021;50:300–5.CrossRef
13.
Zurück zum Zitat Lowery MA, Klimstra DS, Shia J, et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist. 2011;16:1714–20.CrossRef Lowery MA, Klimstra DS, Shia J, et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist. 2011;16:1714–20.CrossRef
14.
Zurück zum Zitat Miller JR, Baggenstoss AH, Comfort MW. Carcinoma of the pancreas; effect of histological types and grade of malignancy on its behavior. Cancer. 1951;4:233–41.CrossRef Miller JR, Baggenstoss AH, Comfort MW. Carcinoma of the pancreas; effect of histological types and grade of malignancy on its behavior. Cancer. 1951;4:233–41.CrossRef
15.
Zurück zum Zitat Jimbo M, Batista PM, Baliff JP, et al. Neoadjuvant chemotherapy and Appleby procedure for pancreatic acinar cell carcinoma: a case report. Case Rep Pancreat Cancer. 2016;2:46–9.CrossRef Jimbo M, Batista PM, Baliff JP, et al. Neoadjuvant chemotherapy and Appleby procedure for pancreatic acinar cell carcinoma: a case report. Case Rep Pancreat Cancer. 2016;2:46–9.CrossRef
16.
Zurück zum Zitat Villano AM, Barrak D, Jain A, et al. Robot-assisted combined pancreatectomy/hepatectomy for metastatic pancreatic acinar cell carcinoma: case report and review of the literature. Clin J Gastroenterol. 2020;13:973–80.CrossRef Villano AM, Barrak D, Jain A, et al. Robot-assisted combined pancreatectomy/hepatectomy for metastatic pancreatic acinar cell carcinoma: case report and review of the literature. Clin J Gastroenterol. 2020;13:973–80.CrossRef
17.
Zurück zum Zitat Yoo C, Kim BJ, Kim KP, et al. Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen. Cancer Res Treat. 2017;49:759–65.CrossRef Yoo C, Kim BJ, Kim KP, et al. Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen. Cancer Res Treat. 2017;49:759–65.CrossRef
18.
Zurück zum Zitat Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.CrossRef Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.CrossRef
19.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRef Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRef
Metadaten
Titel
Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a chemotherapy regimen containing cisplatin and irinotecan
verfasst von
Hiromitsu Maehira
Hiroya Iida
Haruki Mori
Nobuhito Nitta
Aya Tokuda
Katsushi Takebayashi
Sachiko Kaida
Toru Miyake
Akiko Matsubara
Masaji Tani
Publikationsdatum
01.10.2021
Verlag
Springer Singapore
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 6/2021
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-021-01518-z

Weitere Artikel der Ausgabe 6/2021

Clinical Journal of Gastroenterology 6/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.